{"abstract":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to EnZeta Immunotherapies, Inc. of the State of Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2023/08/11/2023-17256.html","cfr_references":[],"citation":"88 FR 54629","comment_url":null,"comments_close_on":"2023-08-28","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 28, 2023 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2023-17256","effective_on":null,"end_page":54630,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2023/08/11/2023-17256.xml","html_url":"https://www.federalregister.gov/documents/2023/08/11/2023-17256/prospective-grant-of-an-exclusive-patent-license-manufacture-distribution-sale-and-use-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2023-17256?publication_date=2023-08-11","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2023-08-11/2023-17256/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":188,"last_updated":"2026-07-25 20:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-08-11/pdf/2023-17256.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-17256.pdf?1691671526","publication_date":"2023-08-11","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2023/08/11/2023-17256.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-08-11T08:03:59Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":54629,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors","toc_doc":"Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.","topics":[],"type":"Notice","volume":88}